athenahealth, Inc. (NASDAQ:ATHN) CEO Jonathan Bush sold 4,000 shares of the stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $139.77, for a total value of $559,080.00. Following the completion of the sale, the chief executive officer now directly owns 319,807 shares of the company’s stock, valued at approximately $44,699,424.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jonathan Bush also recently made the following trade(s):

  • On Tuesday, August 1st, Jonathan Bush sold 4,000 shares of athenahealth stock. The shares were sold at an average price of $143.31, for a total value of $573,240.00.
  • On Monday, July 3rd, Jonathan Bush sold 4,000 shares of athenahealth stock. The shares were sold at an average price of $140.52, for a total value of $562,080.00.

athenahealth, Inc. (NASDAQ:ATHN) traded up 0.27% on Wednesday, reaching $139.67. The company had a trading volume of 248,861 shares. athenahealth, Inc. has a 52-week low of $90.11 and a 52-week high of $158.66. The firm has a market capitalization of $5.58 billion, a price-to-earnings ratio of 177.25 and a beta of 1.79. The stock’s 50-day moving average price is $142.48 and its 200 day moving average price is $128.22.

athenahealth (NASDAQ:ATHN) last announced its quarterly earnings results on Thursday, July 20th. The health services provider reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.12. athenahealth had a net margin of 2.80% and a return on equity of 6.91%. The firm had revenue of $301.10 million during the quarter, compared to analysts’ expectations of $298.68 million. During the same period in the prior year, the company earned $0.34 EPS. The firm’s revenue was up 15.0% on a year-over-year basis. On average, equities analysts anticipate that athenahealth, Inc. will post $1.91 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/06/insider-selling-athenahealth-inc-athn-ceo-sells-4000-shares-of-stock.html.

A number of institutional investors have recently made changes to their positions in ATHN. Janus Henderson Group PLC purchased a new stake in athenahealth during the 2nd quarter worth $713,856,000. BlackRock Inc. boosted its position in athenahealth by 30,642.6% during the 1st quarter. BlackRock Inc. now owns 1,599,847 shares of the health services provider’s stock worth $180,286,000 after purchasing an additional 1,594,643 shares during the period. Morgan Stanley boosted its position in athenahealth by 9.7% during the 1st quarter. Morgan Stanley now owns 4,514,305 shares of the health services provider’s stock worth $508,717,000 after purchasing an additional 397,837 shares during the period. Elliott Management Corp purchased a new stake in athenahealth during the 2nd quarter worth $52,706,000. Finally, Clearbridge Investments LLC boosted its position in athenahealth by 61.8% during the 1st quarter. Clearbridge Investments LLC now owns 908,505 shares of the health services provider’s stock worth $102,379,000 after purchasing an additional 347,133 shares during the period.

Several equities research analysts recently commented on ATHN shares. William Blair reaffirmed a “market perform” rating on shares of athenahealth in a report on Friday, July 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $140.00 price target (up previously from $118.00) on shares of athenahealth in a report on Friday, May 19th. Argus started coverage on athenahealth in a report on Friday, July 7th. They issued a “hold” rating for the company. Citigroup Inc. reiterated a “buy” rating and issued a $163.00 price objective (up from $128.00) on shares of athenahealth in a research report on Monday, June 5th. Finally, J P Morgan Chase & Co set a $136.00 price objective on athenahealth and gave the stock a “hold” rating in a research report on Wednesday, July 19th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and thirteen have given a buy rating to the company’s stock. athenahealth currently has an average rating of “Hold” and a consensus price target of $149.09.

athenahealth Company Profile

athenahealth, Inc provides network-based medical record, revenue cycle, patient engagement, care coordination and population health services. The Company also offers Epocrates and other point-of-care mobile applications. The Company delivers majority of its service offerings through a single instance of cloud-based software, athenaNet.

Insider Buying and Selling by Quarter for athenahealth (NASDAQ:ATHN)

Receive News & Stock Ratings for athenahealth Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for athenahealth Inc. and related stocks with our FREE daily email newsletter.